Merck Sharp + Dohme Corp.

Indu T Bharathan

Yongxin Han

David L Sloman

Derun Li

Anandan Palani

Wensheng Yu

Hongjun Zhang

Thomas H Graham

Ryan D Otte

Abdelghani Achab

Timothy J Henderson

Xavier Fradera

Elisabeth Hennessy

Symon Gathiaka

Xiaoshen Ma

Hua Zhou

Kun Liu

Nunzio Sciammetta

David Jonathan Bennett

Alexander Pasternak

Xianhai Huang

Jongwon Lim

Stephen G Stroud

Paul E Fleming

Liangqin Guo

Francois Soucy

Tricia J Vos

Yongqi Deng

He Xu

Craig R Gibeau

Yongbo Hu

Catherine M White

Kenneth M Gigstad

Meredeth Ann McGowan

Courtney A Cullis

Qinglin Pu

Jeffrey P Ciavarri

Min Lu

Tzu-Tshin Wong

Yingchun Ye

Michael D Sintchak

Mario Girard

Krista E Gipson

Chris Blackburn

Brett A Hopkins

Jouhara Chouitar

Mansoureh Rezaei

Sulagna Sanyal

Natalie D'amore

Janice Lee

Tianlin Xu

Gang Li

Jonathan D Bennett

Bridget A Becker

The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W, W, Y, Z, M, L, C, C, R, R, R, R, R, R, R, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Small molecule inhibitors of KRAS G12C mutant

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W, W, Y, Z, M, L, C, C, R, R, R, R, R, R, Rand the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Growing community of inventors

Somerville, MA, United States of America

Indu T Bharathan